The HemOnc Pulse
The HemOnc Pulse
Advertisement
Saad Z. Usmani, MD, MBA, FACPMyeloma | July 3, 2025
Experts discuss quadruplet therapy, MRD, and evolving transplant decisions in newly diagnosed multiple myeloma.
Nichole TuckerAcute Myeloid Leukemia | June 30, 2025
Dr. Amir Fathi discusses oral regimens and future AML therapy trends in this Editor’s Special of The HemOnc Pulse.
Rahul Banerjee, MD, FACPThe HemOnc Pulse | June 30, 2025
Can tech bridge the cancer care gap? Dr. Banerjee and Dr. Longmire explore solutions for drug accessibility.
Rahul Banerjee, MD, FACPAggressive B-Cell Lymphoma | June 30, 2025
Experts explore CAR T therapy challenges and the future of lymphoma care beyond CD19-targeted treatments.
Rahul Banerjee, MD, FACPAcute Myeloid Leukemia | June 30, 2025
Experts discuss early detection in myeloid malignancies, from current challenges to future innovations.
Rahul Banerjee, MD, FACPMyelodysplastic Syndromes | June 5, 2025
At The HemOnc Pulse Live!, experts debate key controversies in MDS care, from frontline therapy to emerging treatments.
Advertisement
Rahul Banerjee, MD, FACPMyeloma | May 5, 2025
Gurbakhash Kaur, MD joins the host of The HemOnc Pulse Live! for a comprehensive discussion about the RedirecT-1 trial.
Saad Z. Usmani, MD, MBA, FACPThe HemOnc Pulse | November 20, 2024
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Sangeetha Venugopal, MDThe HemOnc Pulse | November 1, 2024
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Naval Daver, MDThe HemOnc Pulse | October 22, 2024
Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology.
Mazyar Shadman, MD, MPHThe HemOnc Pulse | September 27, 2024
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | September 17, 2024
Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting.
Afaf Osman, MDThe HemOnc Pulse | August 9, 2024
Dr. Osman discusses classification and treatment approaches for patients with high-risk MDS.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | July 26, 2024
Rami Komrokji, MD, describes incorporation of molecular data, tailoring treatment by disease risk, and new therapies in MDS.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | May 16, 2024
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse: MRD | September 12, 2024
Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | April 10, 2024
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | April 8, 2024
"Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 28, 2024
It's many different diseases, and it falls across many different specialties, according to the Dr. Goodman.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse: MRD | July 26, 2024
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
Advertisement
Advertisement